All Updates

All Updates

icon
Filter
Funding
Adela scores USD 48 million financing
Precision Medicine
Sep 26, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Sep 26, 2023

Adela scores USD 48 million financing

Funding

  • Genetic testing startup Adela raised USD 48 million in funding, bringing total funds raised to USD 108 million. Labcorp joined the round as a new investor, with existing investors OrbiMed, Decheng Capital, F-Prime Capital, Deerfield Management, and RA Capital Management also participating.

  • The funding will be used to enhance Adela's technological capabilities, commercialize its tissue-agnostic measurable residual disease (MRD) product, and continue developing its multi-cancer early detection product.

  • Adela is focused on developing blood tests for MRD monitoring and early cancer detection. Its genome-wide methylation analysis technology is able to capture genomic information used for the early detection, diagnosis, and management of cancer. The platform captures biologic-relevant genomic data to inform treatment decisions.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.